BIO KEY INTERNATIONAL INC 8K

BIO-key International, Inc. announced improved Q2 2026 results, EMEA-driven growth initiatives, Nasdaq compliance via a reverse stock split, and strengthened liquidity through warrant exercises and debt reduction, while targeting profitability in the second half of 2026.

On August 13, 2026, BIO-key International, Inc. reported its unaudited financial results for the second quarter and first half of 2026, highlighting a 13% year-over-year increase in Q2 revenue to $1.92 million, a gross margin improvement to 87%, and a 51% reduction in Q2 net loss to $0.58 million, while noting that approximately $0.8 million of fully-reserved hardware revenue expected in Q2 was delayed to the second half of 2026. The company described expanding contracts and partnerships in Saudi Arabia, Portugal, Jordan, and the U.S., reiterated its focus on EMEA growth, and indicated it is targeting revenue growth and profitability in the second half of 2026. BIO-key also disclosed capital structure actions including a 1-for-10 reverse stock split completed in Q2 that enabled it to regain compliance with Nasdaq listing rules in July, a warrant inducement transaction completed earlier in the week that raised approximately $2.5 million in gross proceeds and increased cash on hand to over $4.5 million, and a $350,000 reduction in its 2025 note payable via share issuance, and it scheduled an investor conference call for August 14, 2026 at 10:00 a.m. ET to discuss these developments.

Filing Facts

CIK

1019034

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027829

Alert Tier

6